FEMASYS INC (FEMY) Stock Profile — Insider Trades & Financials

EPS$-0.46

Market Cap$24.0M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Kathy Lee-Sepsick

CEO & Executive Director

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and womenâs healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Founded: 2004
Employees: 71

⚡

Core Efficiency

D/E Ratio?

2.53

📊

Profitability Ratios

Current Ratio?

4.53

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Sep 25, 2026 (in 169 days)

Annual Report (10-K) — Based on filing pattern

Sep 25, 2026

Predicted10-K

Mar 31, 2026

10-KQ4 20251d after period end

Mar 31, 2026

10-KFY 202590d after period end

Nov 14, 2025

10-QQ3 20251d after period end

Aug 8, 2025

10-QQ2 20251d after period end

May 8, 2025

10-QQ1 20251d after period end

Mar 27, 2025

10-KQ4 20241d after period end

Mar 27, 2025

10-KFY 202586d after period end

Nov 12, 2024

10-QQ3 20241d after period end

Loading company sections...

FEMASYS INC

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness